טריל 200 מג cr
taro pharmaceutical industries ltd - carbamazepine - טבליות בשחרור מבוקר - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy with the following types of seizure: partial seizures with complex symptomatology ; generalised tonic-clonic seizures; mixed seizure patterns; prophylaxis and treatment of bipolar disorders.
טריל 400 מג cr
taro pharmaceutical industries ltd - carbamazepine - טבליות בשחרור מבוקר - carbamazepine 400 mg - carbamazepine - carbamazepine - epilepsy with the following types of seizure: partial seizures with complex symptomatology ; generalised tonic-clonic seizures; mixed seizure patterns; prophylaxis and treatment of bipolar disorders..
טריל 200
taro pharmaceutical industries ltd - carbamazepine - טבליה - carbamazepine 200 mg - carbamazepine - carbamazepine - epilepsy, trigeminal neurolgia, diabetes insipidus, mania, prophylactic in manic depressive illness.
פטרייה-תי
taro international ltd, israel - terbinafine hydrochloride - קרם - terbinafine hydrochloride 1 %w/w - terbinafine
רוקה-קאר
taro pharmaceutical industries ltd - caffeine; codeine phosphate; paracetamol - קפליות - paracetamol 500 mg; caffeine 30 mg; codeine phosphate 10 mg - paracetamol
קריפטופור 140000 יחבלמל וטרינרי
m.p.vet ltd - paromomycin as sulfate - paromomycin as sulfate 140,000 iu/ml
דולוקסטין סנדוז 30 מג ג'י.אר.סי
novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
דולוקסטין סנדוז 60 מג ג'י.אר.סי
novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
קזודקס 50 מג
taro international ltd, israel - bicalutamide - טבליה - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.
ארימידקס
taro international ltd, israel - anastrozole - טבליות מצופות פילם - anastrozole 1.0 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.